Objectives: To validate the PRISM (Pictorial Representation of Illness and Self Measure) tool, a novel visual instrument, for the assessment of health-related quality of life in dermatological inpatients compared with the Dermatology Life Quality Index (DLQI) and the Skindex-29 questionnaires and to report qualitative information on PRISM.
Instruments developed in other disciplines are inadequate to assess HRQOL in dermatology; therefore, skin-specific questionnaires such as the Dermatological Life Quality Index (DLQI) and the Skindex-29 have been developed and validated. These selfreport HRQOL questionnaires, which validly and sensitively assess appearance, itch, and functional impairment, have gained clinical acceptance and are regularly used in clinical trials. 2 These questionnaires have limitations. Because they were developed to assess inflammatory skin diseases, they perform best in this limited scope of skin disease. Standardized questions intended to apply to a range of conditions often do not address disease-specific concerns. Repeated assessments tend to exhaust the patient's willingness to complete the questionnaires, a phenomenon known as respondent burden. Computation of HRQOL score from questionnaires is cumbersome and not intuitive for the clini-cian. Written qualitative questionnaires may be limited to relevant use within the cultural region for which they were developed. 3 Most notably, these questionnaires work with set questions, in which the answers contribute to the total score but yield little information about the particular individual's main concern and specific needs.
Recently, PRISM (Pictorial Representation of Illness and Self Measure), a novel visual instrument to assess the global illness impact, has been successfully validated for several chronic diseases including rheumatoid arthritis, 4 chronic obstructive pulmonary disease, 5 and systemic lupus erythematosus. 6 Data and clinical experience with this instrument indicate that it is not only easy to use but can be used by practicing clinicians to assess therapeutic effect as well as to individualize treatment goals. Beyond the dimension of HRQOL assessment, the PRISM tool offers specific information that may be used to tailor treatment to individual needs.
As a first step toward clinical use of the PRISM tool in skin diseases, we sought to validate PRISM as an HRQOL assessment tool in dermatological inpatients compared with the well-established and validated DLQI and Skindex-29 HRQOL questionnaires. We were further able to assess the burden of illness in these patients by analyzing their plain-text answers to PRISM questions, using the Mayring inductive qualitative context analysis. 7 
METHODS

PATIENTS
Following approval by the institutional review board of the Canton of Zürich, Zürich, Switzerland, we asked all patients admitted consecutively to our dermatological inpatient ward from July 2005 to July 2006 for a projected stay of at least 7 days to participate in the study. Patients with severe dementia, blindness, and deafness or inability to communicate in the local language were excluded. Following written informed consent, all enrolled patients completed the PRISM 4, 6, 8 task with the investigators (B.M. or S.S.) at the following time points: at admission, once every week throughout their inpatient stay, and finally at discharge. At the same time points, patients filled in the German versions of the validated dermatological HRQOL questionnaires, the Dermatology Life Quality Index (DLQI) and Skindex-29.
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THE PRISM TOOL
We presented the PRISM tool as described 4, 6, 8 and illustrated in Figure 1 . Patients were shown a white A4-sized metal board with a yellow circle (diameter, 6 cm) at the bottom right-hand corner. Each patient was asked to imagine that the plate represented his or her life at this moment in time, with the circle representing his or her "self." Patients were then handed a red circular disk (diameter, 4 cm). They were asked to imagine that the red disk represented their illness and were asked "Where would you put the illness in your life at this moment?" The main outcome measure was the distance between the yellow circle and the red disk, called the Self-Illness Separation (SIS) distance, measured between the centers of the circles and ranging from 0 to 270 mm. Higher SIS distances corresponded to lesser perceived impairment. In addition, patients were asked to explain in their own words why they put the red disk at that specific position and what the chosen SIS distance meant to them. This qualitative information was transcribed verbatim by the examiner. Then, the examiner asked the patient to put the disk where he or she thought the illness would be on the day of discharge. Once again, the examiner asked the patient what this SIS distance meant and noted the patient's words verbatim. The completion of the PRISM tasks was speedy and intuitive to the patient.
DLQI AND SKINDEX-29
The DLQI is a well-established, brief, 10-item HRQOL questionnaire originally developed for and currently frequently used in many clinical studies in a variety of skin diseases. 10 The German version was used as validated previously.
11 Skindex-29 is a refined version of a previous 61-item instrument.
12 This 29-item, self-administered questionnaire assesses HRQOL of dermatological patients in 3 domains: burden of symptoms, social and physical functioning, and emotional responses. The German version was used as validated previously. 13 We administered the Skindex-29 and DLQI HRQOL questionnaires and calculated the results following protocols described elsewhere. 9, 10, 12, 14 For statistical analyses of the Skindex-29 scores, we considered the global sum score as well as the subscores of each of the 3 dimensions (burden of symptoms, social and physical functioning, and emotional responses). For both of these well-established questionnaires, higher scores reflect greater impairment. Questionnaires with more than 10% missing items were excluded from analysis. In questionnaires with up to 10% missing items, we performed item-mean imputation as described elsewhere.
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VALIDATION OF THE PRISM TASK
As a first step, we assessed correlation between PRISM SIS scores and the Skindex-29 and DLQI scores using the Spearman rank correlation coefficient (). We also assessed correlation among the 3 instruments for each single point in time when all 3 were administered.
As a second step, we assessed each instrument's sensitivity to change during the course of inpatient stay as expressed by differences in mean percentages of that instrument between admission and discharge. Sensitivity to change was also expressed by Cohen effect size (d) 16 (difference in the mean values between admission and discharge divided by the mean [SD] Illness Life at the moment SIS Self Figure 1 . Pictorial Representation of Illness and Self Measure (PRISM). The PRISM tool consists of a white A4-sized metal board representing the "patient's life at the moment," with a yellow circle representing the patient's "self." A red disk representing "illness" is placed onto the board by the patient in response to the question "Where would you put the illness in your life at this moment?" The main outcome measure is the distance between the centers of the yellow circle and red disk, called the Self-Illness Separation (SIS) distance, ranging from 0 to 270 mm, with higher SIS distances reflecting lesser impairment.
of the 2 time points). We compared paired proportions using the Wilcoxon signed-rank test. PϽ.05 was considered statistically significant.
RELIABILITY OF DLQI AND SKINDEX-29
To assess the internal consistency of the 2 HRQOL questionnaires in our cohort, we used Cronbach ␣. We performed statistical analyses for all patients together as well as for the "dermatitis," "psoriasis," "leg ulcer," and "skin tumor" diagnosis subgroups using SPSS for Windows 11.5 (SPSS Inc, Chicago, Illinois) and Microsoft Excel 2000 (Microsoft Corp, Redmond, Washington).
QUALITATIVE PRISM DATA ANALYSIS
We transcribed the patients' spoken explanations verbatim for both PRISM SIS scores and treatment expectations and analyzed them according to the method of inductive qualitative context analysis described by Mayring. 7 We then assigned these responses to different subcategories, specifically to 4 response categories describing the significance of the PRISM SIS score (symptom intensity, adjustment, self-image, and handicap) and into 3 response categories describing treatment expectations (symptom reduction, less handicap, and no treatment expectation). After being assigned to these various categories, the responses were independently rated by 2 raters to test reliability. The correlation between the findings of these 2 raters was calculated by Cohen .
17 The 4 PRISM-related response categories had a correlation of =0.95, while the 3 treatment expectations categories showed a correlation of =0.91. These results indicated high interrater accordance on both measures and high reliability of categorizing individual responses into more general terms. Figure 2 shows the number of enrolled patients who completed the PRISM, DLQI, and Skindex-29 questionnaires, as well as follow-up evaluations for each of these measures, exclusions from the study, and number lost to follow-up. Most patients lost to follow-up were discharged before completing 1 week of hospitalization and therefore were not assessed a second time. Patient characteristics and diagnoses are provided in Table 1 . Other diagnoses (n=56 [30%]) comprised cutaneous eruptions from drug use, hypodermitis, prurigo, urticaria, vasculitis, acne inverse, dyskeratosis follicularis, dermatomyositis, and lichen sclerosus et atrophicans.
RESULTS
PATIENTS
RELIABILITY OF SKINDEX-29 AND DLQI
Both HRQOL measures showed a high degree of internal consistency as expressed by Cronbach ␣, both overall and in several subscores (DLQI, ␣=0.88; Skindex-29 global score, ␣=0.96; symptoms subscore, ␣=0.85; social functioning subscore, ␣ = 0.93; and emotions subscore, ␣=0.91). This suggests that both were equally effective at capturing patient responses. 
SENSITIVITY TO CHANGE
All 3 instruments showed a significant reduction in the patients' burden of illness during hospitalization (PϽ.001, Wilcoxon signed-rank test) (Figure 2 ). For patients overall, PRISM showed the highest sensitivity to change between admission and discharge as expressed by Cohen effect size, with PRISM showing an effect size of d=0.67 compared with d = 0.59 for Skindex-29 and d =0.54 for DLQI. In the leg ulcer, psoriasis, and tumor diagnosis subgroups, PRISM again showed the highest effect size of the 3 instruments. In patients with dermatitis, by contrast, the HRQOL questionnaires showed a higher effect size than PRISM (Figure 3 and Table 3 ).
QUALITATIVE ASPECTS OF BURDEN OF ILLNESS
Patients who were asked at admission about such qualitative measures as their treatment expectations and fears answered in terms that suggested patterns by diagnosis group. Patients with leg ulcer mainly hoped to achieve symptom reduction. Patients with dermatitis most frequently expected a reduction in handicap. Among patients with psoriasis, a striking 28% (6 patients) did not express any expectations. Patients' primary negative expectations also varied according to diagnosis. Patients with psoriasis and leg ulcer were most likely to fear selfimage impairment. Patients with tumor most frequently reported concerns about adjustment. Qualitative context analysis according to Table 4 gives the patient answers as assigned to categories for dimensions of suffering and treatment expectations, with sample responses.
COMMENT
The aim of this study was to validate the PRISM tool for assessment of HRQOL in dermatologic inpatients. Reliability of the HRQOL questionnaires in our cohort was high, as expressed by Cronbach ␣ (Table 3) . Correlation between PRISM and the skin-specific HRQOL questionnaires was fair, with Spearman = 0.426 for Skindex-29 and = 0.304 for DLQI. We had expected the correlation between PRISM and the 2 questionnaires to be moderate to good but not perfect because PRISM does not measure precisely the same HRQOL items as the selfadministered questionnaires, but rather assesses the patient's global burden of suffering. In addition, the correlation between the 2 HRQOL comparison questionnaires themselves-each designed to assess quality of life in skin diseases-was relatively low at =0.674 (data not shown). With these factors in consideration, correlation between PRISM and the comparison HRQOL questionnaires may be regarded as high. Validation of the PRISM tool was thus achieved.
To our knowledge, there have been no other studies investigating correlation between PRISM and DLQI or Skindex-29 to date. In a PRISM validation study, 18 in 568 outpatients with various chronic illnesses, the correlation between PRISM scores and the Medical Outcomes Abbreviations: DLQI, Dermatology Life Quality Index; PRISM, Pictorial Representation of Illness and Self Measure. a Data are given as Spearman rank correlation coefficient unless otherwise specified. The highest correlation between PRISM and Skindex-29 scores was for patients with dermatitis or leg ulcer ( = 0.614 and 0.554, respectively), and the highest correlation between PRISM and DLQI scores was for patients with psoriasis or tumor ( = 0.418 and 0.399, respectively).
b Includes 2 patient population numbers for comparisons with PRISM and Skindex-29 and PRISM and DLQI, respectively. Study 36-Item Short-Form Health Survey (SF-36) subscores ranged from =0.177 to 0.392-notably lower than the comparable correlations for the questionnaires in our study, potentially because of a wider range of disease conditions included. The correlation between PRISM and Hospital Anxiety and Depression (HADS) depression scale in the same cohort was similarly low at =0.312. The correlation of the 3 instruments used in our study was thus higher than to be expected from previous studies in other disease conditions. All 3 instruments we used proved capable of significantly detecting improvement in HRQOL during hospitalization. In measuring overall changes in inpatient HRQOL, the PRISM tool performed equally as well as the self-administered questionnaires. In measuring effect size, PRISM was the most sensitive tool, both across all groups and in most diagnosis subgroups. An additional advantage of the PRISM tool is its ability to bridge crosscultural differences. While such differences exist for all HRQOL questionnaires, 3 PRISM may be the least influenced by cultural differences because it uses a more global, intuitive, and graphic-indeed, pictorial-assessment of HRQOL.
In a recent study by Reimus et al, 19 patients with psoriasis were offered the original PRISM board with the key difference of variable-sized illness disks. By offering patients the additional factor of expressing the impact of illness by changing disk size, the study extracted meaning from the distance measure SIS. In 59 patients with psoriasis, the study by Reimus et al 19 showed little correlation between the Psoriasis Area and Severity Index (PASI) and PRISM (=0.14) on the one hand and between PASI and the Health Monitor Questionnaire scores (0.10-0.16) on the other, offering further evidence that the changeable disk size reduced the significance of the distance measure SIS. We therefore do not recommend the use of this revised version of PRISM.
An additional challenge to HRQOL assessments, one that has been reported before, is the often limited association between physical findings as reported by the physician and subjective quality of life issues as reported by the patient. Considering this stumbling block to the possibility of ever finding a gold standard for quality of life assessments, 20 we can at least conclude that the 3 instruments in our study correlated well with one another, and all seem potentially useful for HRQOL assessment in dermatological inpatients. Adjustment Control of and adjustment to disease "Not so bad," "not limiting," "not annoying," "already adapted to illness"
44
Self-image Whole person in terms of integration of disease, changes of the self, suffering, and existential fears "The disease is part of me," "omnipresent," "totally central," "dominates the person," "trembling uncertainty," "compelling"
48
Handicap Physical activity, social participation "Job problems," "family problems," "limited social contact," "avoidance of swimming pools," "loss of independence"
17
Treatment Expectations Symptom reduction
Expectations of symptom improvement up to complete healing "Less pain," "less itching," "less alterations of the skin," "disease disappeared," "forgotten"
69
Less handicap Better physical and social functioning as well as improved coping "Everyday activities possible," "more autonomy," "higher working ability," "more activity with family, friends," "swimming," "higher quality of life," "better coping with the illness," "less limitation"
37
No expectations No changes by treatment expected "No changes," "no or only little improvement," "the illness will persist," "slight hope" 
